Janet Sasso

Janet Sasso, Information Scientist at CAS

Janet M. Sasso earned her B.S. in Biology from The Ohio State University. She also holds her Master of Public Health from OSU where she focused her research on public health equity and education. She joined CAS in 2006 as an Information Scientist in the life sciences department curating pharmacology, pharmaceutical, environmental science, and toxicological research information. She and her team have recently studied the landscape of the gut-brain alliance in respect to mental and gastrointestinal health and disorders.

Information Scientist/CAS

Janet M. Sasso earned her B.S. in Biology from The Ohio State University. She also holds her Master of Public Health from OSU where she focused her research on public health equity and education. She joined CAS in 2006 as an Information Scientist in the life sciences department curating pharmacology, pharmaceutical, environmental science, and toxicological research information. She and her team have recently studied the landscape of the gut-brain alliance in respect to mental and gastrointestinal health and disorders.

Webinar on Gut Microbiome-Brain Alliance

Explore the fascinating connection between the gut microbiome and the brain in this webinar featuring experts from CAS, Bayer, and Caltech. Learn how the gut-brain axis influences health from IBS to autism and how microbiome manipulation can offer new therapeutic strategies.

| Webinar

GettyImages-1415655606_CAS-Insights-Hero-Image

The gut microbiome is a complex ecosystem of trillions of bacteria that live in our digestive tracts with health benefits like immunity, improved mental health, and therapeutic options. In recent years, there has been a growing interest in the potential of microbiome therapies to treat a variety of diseases. As our understanding of the gut microbiome continues to grow, we can expect to see more advances in microbiome therapies in the years to come.

| Article

Exosome-acs-webinar

Discover how exosomes, nature's lipid nanoparticles, are reshaping drug delivery and treatment of diseases from cancer to cardiovascular disease and beyond. Learn from experts at Mayo Clinic, Direct Biologics, and Aruna Bio in our recent ACS webinar. Watch the recording and read the full Insight Report now.

| Webinar

Exosome CAS Insights article 3

Landscape view of emerging contributors, companies, and researchers in the emerging field of exosome research. This article overviews key players in diagnostics and therapeutic fields of exosome research with a deeper look into the current clinical pipeline.

| Article

Molecular Glues Video Player Image

Learn more about the expert panel discussion on molecular glues and targeted protein degradation. Expert panelists include Dr. Benjamin Ebert, the chair of Medical Oncology at the Dana-Farber Institute, Dr. Phil Chamberlain, the co-founder, President, and CEO of Neomorph, and Janet Sasso, an information scientist specializing in Life Sciences at CAS.

| Webinar

"When you’re finished changing, you’re finished." Business leaders likely weren't the intended audience when Benjamin Franklin uttered his now famous quote. However, his words likely resonate deeply with leaders in today's rapidly evolving marketplace who know that for their business to thrive, they must be prepared to adapt and embrace new technologies.

| Article

depiction of spike protein region on a Covid virus

As COVID-19 cases rise again worldwide, the Omicron subvariant BA.5 is currently the dominant strain. This blog explores some key mutations that increase transmission, evade protective antibodies, and increase the rate of (re)infection.

| Article

RNA Medicines blog thumbnail

Molecular glues have been used to uncover new therapeutic agents. Because of their targeted protein degradation that holds them together, these glues have exciting potential in uncovering new drugs to fight cancer, immune diseases, and more.

| Article

Monkeypox virus cellular depiction

With recent headlines on monkeypox, learn more about the research landscape, scientific profiles, and currently available therapies. A deeper understanding of the published science enables clarity and insight on this emerging news story. 

| Article

photo showing sample vials of RNA based therapeutics

We are in the midst of a therapeutic revolution, according to the authors of a recent review article in Frontiers in Bioengineering and Biotechnology. They were commenting on the rapid expansion of RNA therapeutics in modern research and clinical development, driven in part by interest in RNA COVID-19 vaccines in the ongoing SARS-CoV-2 pandemic.  

| Article

Nurse administering booster vaccine

With recent mRNA booster recommendations, many ask if they should get a COVID-19 booster and what the science shows? This blog explains the science of boosters, reviews current recommendations, and examines recent research.

| Article

Load More